Epigenomics AG.(AACR Roundup)

Epigenomics AG, of Frankfurt, Germany, presented data from its colorectal cancer screening test development program showing that a modification of the assay procedure and rules for test result interpretation significantly improved the performance of its DNA-Methylation biomarker Septin 9 for the early detection of colorectal cancer in blood plasma. Using those modifications Septin 9 detected 70 percent (91 out of 130) of the colorectal cancers in the study and was falsely …